• black-back-closed-envelope-shape
  • White Instagram Icon
  • White Facebook Icon
  • White LinkedIn Icon

Copyright ©2019 by Sanomics Limited. All rights reserved.


Your cancer genome changes in response to therapies.

Before Guardant 360, the only option available to understand these changes was to have repeated tissue biopsies.


Guardant360 is able to...

identify somatic mutations of 73 genes, proven to be clinically relevant, and reports on microsatellite instability (MSI) status through the detection of circulating tumor DNA (ctDNA) in blood specimens using NGS technologies.

Why use Guardant360®?



MSI status

99.99% Analytical Specificity

Advantages of Guardant360


WHO is it SUITED for?

Gene List

Advanced cancer patients who require complete genotyping


Insufficient tissue biopsy in quantity or quality, or tissue is unobtainable at diagnosis


Archived tissue older than 6 months


Unresponsive to one or more lines of therapy or intervention since the last biopsy


Time to treatment is critical and the decision is required within 2 weeks.


Patient who prefer non-invasive genomic profiling or is unwilling to undergo invasive biopsies.